University of Patras
Μορφολογική μελέτη του ρόλου των ενζύμων μεθυλίωσης καταλοίπων αργινίνης στον καρκίνο προστάτη: συσχέτιση της έκφρασής τους με κλινικές και παθολογοανατομικές παραμέτρους
Abstract
dc:descriptionA review of histology slides of radical prostatectomy specimens retrieved from the archive of P.G.N.P. Hospital was performed as part of the study of the role of arginine methyltransferase in prostate cancer cases. Consequently, it was created a tissue biobank, consisting of fully characterized cases (from a pathology perspective), according to the latest guidelines of ISUP 2019 and 8th edition of AJCC. This sample, along with cases derived from MD Anderson Cancer Center that were acquired after a material transfer agreement, (#MT2017-17807) were stained immunohistochemically with the antibodies PRMT1, PRMT2, PRMT4/CARM1, PRMT7 and JMJD6. Additionally, collection of selected cases (high grade) was studied with Epithelial to Mesenchymal Transition markers, such as ZEB1, TWIST1, E-cadherin, mediators of the cell cycle, like cyclin D1, RB/pRB, p53, regulators of androgen signal transduction (AR/pAR, NKX3.1, PSA) and proliferation index ki67. Afterwards, it was conducted statistical analysis of the results, comparing the enzymes expression levels in the neoplastic foci with the normal prostate tissue of peripheral zone and lymphnode metastasis. Then, the expression was correlated with clinical and pathological parameters, such as Prognostic Grade Group/ Gleason score, pathology stage (T) and the preoperative hormonal therapy. Moreover, it was highlighted a correlation of PRMT1, CARM1, PRMT7 and JMJD6 expression and EMT- and cell cycle molecules. Week correlations between all the members of PRMT family were noted. In order to investigate the expression of the above molecules at the genetic level, data from Cancer Genome Atlas data base were retrieved and the mRNA expression levels of methyltransferase enzymes were compared in neoplastic prostate tissue and normal prostate specimens, while they were associated with pathology stage and Prognostic Grade Group. The results of the comparison demonstrated deregulation of PRMTs gene expression, with PRMT7 elevation and a decrease in PRMT2 and JMJD6 expression. As far as stage, PRMT7 seemed to decline with the upgrading of stage, while CARM1 was increased. Finally, CARM1 expression increased with the progress of grade. In conclusion, the results who came up, support the notion that PRMTs are deregulated during the prostate cancer progression, while a possible interaction with EMT mediators was observed. Further studies elucidating the functional role of these molecules are needed in light of therapeutic targeting of arginine methylation
Degree
thesis:*- Grantor dc:publisher
- University of Patras
- Year dc:date
- 2022
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Grypari, Ioanna-Maria
- Γρυπάρη, Ιωάννα-Μαρία
Subjects
dc:subject × 24- Μεθυλοτρανσφεράσες της αργινίνης
- Καρκίνος προστάτη
- Ορμονοανθεκτικός καρκίνος προστάτη
- ΜΟΡΦΟΛΟΓΙΚΗ ΜΕΛΕΤΗ
- Ιστική βιοτράπεζα
- Ανοσοϊστοχημική μελέτη
- Βάση δεδομένων mRNA
- Επιθηλιακή προς μεσεγχυματική μετατροπή (ΕΜΤ)
- Protein Methyltransferase of Arginine
- Prostate cancer
- Castrate Resistant Prostate Cancer
- MORPHOLOGICAL STUDY
- Tissue Biobank
- Immunohistochemic analysis
- Data base mRNA
- Epithelial to mesenchymal transition
- Βασική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Παθολογοανατομία
- Μοριακή ιατρική
- Basic Medicine
- Medical and Health Sciences
- Pathology
- Molecular Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/51684